Key facts
- It has raised $11.1M; the latest was Later Stage VC ($2.1M) in Jul 2025.
- Notable investors include Széchenyi, Development and Innovation, Development and Innovation Office, Lief Holdings, National Office for Research — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for VRG Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for VRG Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VRG Therapeutics
Developer of a mini-protein technology designed to bring new treatments for poorly managed diseases. The company's technology optimizes peptides of natural origin to create cellular and gene therapy products that treat central nervous system diseases, enabling medical professionals to tackle diseases through mechanisms that conventional biopharmaceutical approaches cannot achieve.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Employees
- 24
- Website
- vrgtherapeutics.com/
- Ownership
- Privately Held (backing)
VRG Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VRG Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VRG Therapeutics in its N-PORT filings yet. We sweep new filings monthly.